Tackling cancer stemness with nanotechnology in the era of precision medicine
BMEMat · 19.05.2026
DOI: 10.1002/bmm2.70099 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMEMat, online erschienen am 19.05.2026. Verfasst von Shaolei Guo und 9 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer stem cells (CSCs) represent a highly plastic therapy‐resistant tumor subpopulation that drives therapy resistance, disease recurrence, and metastasis. This review critically evaluates how nanotechnology‐based strategies are gaining traction in addressing key biological and translational barriers associated with CSC targeting in the context of precision oncology. On the diagnostic frontiers, nanoplatforms enable CSC detection through biomarker‐assisted and ‐independent functional imaging approaches, as well as liquid biopsy modalities that capture CSC‐associated circulating tumor cells, circulating tumor DNA (ctDNA), and extracellular vesicles, thereby supporting non‐invasive disease stratification and monitoring. Across therapeutic modalities, nanotechnology‐assisted delivery of mono‐ and combination chemo‐, radio‐, targeted, photothermal, photodynamic and sonodynamic therapies effectively sensitizes CSCs and eliminate them by enhancing intratumoral drug accumulation. Niche‐focused nanostrategies harness stimuli‐responsive activation of nanoparticles tailored to CSC‐associated microenvironmental cues, and modulate hypoxia, redox balance, metabolic plasticity, and stemness signaling as central mechanisms for disrupting CSC maintenance. Nanotechnology‐assisted immunotherapies, including checkpoint‐directed delivery, immune modulation, nano‐vaccines, and engineered cell strategies, represent emerging approaches to reprogram CSC‐immune interactions and enhance anti‐tumor immune responses. Nanoparticle physicochemical properties, pharmacokinetics, biodistribution, and immune interactions are critical parameters that govern their therapeutic efficacy and safety. Importantly, despite strong preclinical success, the clinical translation of nanotherapeutics remains constrained by limitations of preclinical models, regulatory hurdles, manufacturing complexity, and cost‐ineffectiveness. Overall, the evidence supports the view that rational, biomarker‐informed nanoplatform design, integrated with patient‐specific tumor features, represents a viable path toward precision CSC‐targeted therapies with improved clinical responses and durable cancer control.
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Guo, S., Yao, S., Meng, L., Chen, C., Lu, Y. L., Lu, R., Zahid, K. R., Raza, U., Wu, Q., & Chen, W. (2026). Tackling cancer stemness with nanotechnology in the era of precision medicine. BMEMat. https://doi.org/10.1002/bmm2.70099
Vancouver
Guo S, Yao S, Meng L, Chen C, Lu YL, Lu R, et al. Tackling cancer stemness with nanotechnology in the era of precision medicine. BMEMat. 2026. doi:10.1002/bmm2.70099
BibTeX
@article{Guo2026,
author = {Guo, Shaolei and Yao, Shun and Meng, Lihui and Chen, Chunyuan and Lu, Yuechu Lucinda and Lu, Rong and Zahid, Kashif Rafiq and Raza, Umar and Wu, Qingzhi and Chen, Wenli},
title = {Tackling cancer stemness with nanotechnology in the era of precision medicine},
journal = {BMEMat},
year = {2026},
doi = {10.1002/bmm2.70099}
}
EUVIMED